RGLS Panoramica delle azioni Regulus Therapeutics Inc. è una società biofarmaceutica in fase clinica che si concentra sulla scoperta e sullo sviluppo di farmaci che hanno come bersaglio i microRNA per il trattamento di una serie di malattie negli Stati Uniti. Maggiori dettagli
Analisi del rischio + 1 più rischio
Vedi tutti gli assegni di rischio {"enabled":false,"variant":{"name":"disabled","enabled":false},"ready":false,"error":null}
Catturate i vostri pensieri, i link e la narrativa aziendale
Regulus Therapeutics Inc. Concorrenti Storia dei prezzi e prestazioni
Riepilogo dei massimi, dei minimi e delle variazioni dei prezzi delle azioni per Regulus Therapeutics Prezzi storici delle azioni Prezzo attuale dell'azione US$1.13 Massimo di 52 settimane US$3.79 Minimo di 52 settimane US$0.83 Beta 1.58 Variazione di 1 mese -19.86% Variazione a 3 mesi -24.67% Variazione di 1 anno -27.56% Variazione a 3 anni -54.82% Variazione a 5 anni -86.39% Variazione dall'IPO -99.78%
Notizie e aggiornamenti recenti
New minor risk - Share price stability Feb 03
CEO & Director recently bought US$54k worth of stock Feb 02
Regulus Therapeutics Announces Positive Clinical and Regulatory Updates from its Autosomal Dominant Polycystic Kidney Disease Program for Farabursen (RGLS8429) Jan 29
Regulus Therapeutics Announces Completion of Enrollment in Fourth Cohort of Phase 1B Multiple-Ascending Dose (Mad) Clinical Trial of Rgls8429 for the Treatment of Patients with Autosomal Dominant Polycystic Kidney Disease Oct 08
Companies Like Regulus Therapeutics (NASDAQ:RGLS) Are In A Position To Invest In Growth Sep 28
New minor risk - Profitability Aug 15 Vedi altri aggiornamenti
New minor risk - Share price stability Feb 03
CEO & Director recently bought US$54k worth of stock Feb 02
Regulus Therapeutics Announces Positive Clinical and Regulatory Updates from its Autosomal Dominant Polycystic Kidney Disease Program for Farabursen (RGLS8429) Jan 29
Regulus Therapeutics Announces Completion of Enrollment in Fourth Cohort of Phase 1B Multiple-Ascending Dose (Mad) Clinical Trial of Rgls8429 for the Treatment of Patients with Autosomal Dominant Polycystic Kidney Disease Oct 08
Companies Like Regulus Therapeutics (NASDAQ:RGLS) Are In A Position To Invest In Growth Sep 28
New minor risk - Profitability Aug 15
New minor risk - Market cap size Aug 06
Price target increased by 49% to US$11.00 Jun 25
Regulus Therapeutics Inc. Announces Positive Topline Data from the Third Cohort of Patients in its Phase 1b Multiple-Ascending Dose (MAD) Clinical Trial of RGLS8429 for the Treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD) Jun 24
Bio-Techne Corporation and Regulus Therapeutics Inc. Announces Continued Technical and Clinical Collaboration May 23
Regulus Therapeutics Inc. Announces Promotion of Rekha Garg to Chief Medical Officer May 18 Regulus Therapeutics Inc. has filed a Follow-on Equity Offering in the amount of $50 million. May 11
Regulus Therapeutics Inc., Annual General Meeting, May 16, 2024 Apr 21
New major risk - Revenue and earnings growth Mar 18
New major risk - Shareholder dilution Mar 17
Regulus Therapeutics Inc. announced that it has received $100.000267 million in funding from a group of investors Mar 15 Regulus Therapeutics Inc. announced that it expects to receive $100 million in funding from a group of investors
Insufficient new directors Dec 20
Regulus Therapeutics Announces First Patient Dosed in Third Cohort of Phase 1B Multiple Ascending Dose (Mad) Clinical Trial of RGLS8429 for the Treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD) Nov 03
Regulus Therapeutics Announces Completion of Enrollment in Second Cohort of Phase 1B Multiple-Ascending Dose Clinical Trial of RGSL8429 for the Treatment of Patients with Autosomal Dominant Polycystic Kidney Disease (Madpkd) Sep 14
New major risk - Financial position Aug 10
Regulus Therapeutics, Inc. Announces First Patient Dosed in Second Cohort of Phase 1b Multiple Ascending Dose Clinical Trial of RGLS8429 for the Treatment of Autosomal Dominant Polycystic Kidney Disease Jun 28
Regulus Therapeutics Inc. Appoints Preston S. Klassen to President and Head of Research and Development Jun 13
Regulus Therapeutics Advances to Cohort 2 of Phase 1B Multiple-Ascending Dose Clinical Trial of RGLS8429 for the Treatment of Autosomal Dominant Polycystic Kidney Disease May 17
Regulus Therapeutics Inc. Announces Resignation of Simos Simeonidis as Board Member Dec 13
Regulus Therapeutics Inc. Announces Executive Changes Nov 30
Insufficient new directors Nov 16
Regulus Therapeutics Inc. to Report Q3, 2022 Results on Nov 10, 2022 Nov 04
Regulus Therapeutics Inc. Announces First Patient Dosed in Phase 1B Multiple-Ascending Dose Clinical Trial of RGSL8429 for the Treatment of Autosomal Dominant Polycystic Kidney Disease Nov 03
Regulus Therapeutics Inc. Announces Positive Topline Safety and Pharmacokinetic Data from the Phase 1 Single-Ascending Dose (Sad) Clinical Trial of Rgls8429 for the Treatment of Autosomal Dominant Polycystic Kidney Disease Sep 13
Regulus surges 15% after Phase 1 data for kidney disease candidate Sep 12
Price target increased to US$20.00 Aug 12
Regulus Therapeutics GAAP loss per share narrows Aug 11
Regulus Therapeutics Inc. to Report Q2, 2022 Results on Aug 11, 2022 Aug 05
Insufficient new directors Aug 01
Price target increased to US$20.00 Jul 23
Insufficient new directors Jul 02
Regulus Therapeutics Announces Receipt of FDA Orphan Drug Designation for RGLS8429 for the Treatment of Autosomal Dominant Polycystic Kidney Disease Jun 22
Regulus Therapeutics Inc. Announces First Subject Dosed in Phase 1 Single-Ascending Dose (SAD) Clinical Trial of RGLS8429 for the Treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD) Jun 14
Regulus Therapeutics Inc. Announces FDA Acceptance of Investigational New Drug Application for RGLS8429 for the Treatment of Autosomal Dominant Polycystic Kidney Disease May 12
Regulus Therapeutics Inc. to Report Q1, 2022 Results on May 12, 2022 May 06
Price target increased to US$1.50 Apr 27
Full year 2021 earnings: EPS misses analyst expectations Mar 13
Regulus Therapeutics Inc. to Report Q4, 2021 Results on Mar 10, 2022 Mar 06
Regulus Therapeutics Announces Completion of Enrollment in Phase 2 Clinical Trial of Lademirsen for Alport Syndrome Feb 25
Regulus Therapeutics Inc. Announces Successful Completion of Pre-Ind Meeting with FDA for Rgls8429 Jan 22
Regulus Therapeutics Inc. announced that it has received $34.624999 million in funding from New Enterprise Associates, Inc., Federated Hermes, Inc. Dec 01
Regulus Therapeutics Inc. announced that it expects to receive $34.624999 million in funding from New Enterprise Associates, Inc., Federated Hermes, Inc. Nov 25
Does Regulus Therapeutics (NASDAQ:RGLS) Have A Healthy Balance Sheet? Oct 12
Director Jason Nunn has joined 5th company board Sep 02
Director Jason Nunn has joined 5th company board Sep 02
Director Jason Nunn has joined 5th company board Sep 02
Director Jason Nunn has joined 5th company board Sep 02
Consensus forecasts updated Aug 17
The Read On Regulus Therapeutics Aug 03
Regulus Therapeutics Presents Additional Data from its Autosomal Dominant Polycystic Kidney Disease (ADPKD) Program at PKD Connect 2021 Jun 26
Regulus Therapeutics Inc. to Present Additional Data from Its Autosomal Dominant Polycystic Kidney Disease (ADPKD) Program At PKD Connect 2021 Jun 22
We Think Shareholders Are Less Likely To Approve A Large Pay Rise For Regulus Therapeutics Inc.'s (NASDAQ:RGLS) CEO For Now Jun 09
Regulus Therapeutics Inc. Announces Incremental Update of Autosomal Dominant Polycystic Kidney Disease Program May 22
Regulus Therapeutics Announces Top-Line Data from the First Cohort of Phase 1b Clinical Trial of RGLS4326 for the Treatment of Patients with Autosomal Dominant Polycystic Kidney Disease (ADPKD) May 04
Regulus reports top-line data from early-stage RGLS4326 trial in polycystic kidney disease May 03
Analysts update estimates Mar 17
Auditors Are Concerned About Regulus Therapeutics (NASDAQ:RGLS) Mar 13
Full year 2020 earnings released: US$0.45 loss per share (vs US$1.08 loss in FY 2019) Mar 11
Revenue beats expectations, earnings disappoint Mar 11
Introducing Regulus Therapeutics (NASDAQ:RGLS), The Stock That Zoomed 101% In The Last Year Mar 10
New 90-day high: US$1.94 Feb 17
Regulus Therapeutics Inc. Announces Completion of Enrollment in First Cohort of Phase 1B Clinical Trial of Rgls4326 for the Treatment of Patients with Autosomal Dominant Polycystic Kidney Disease Feb 11
Regulus Therapeutics Inc. Appoints Alice S. Huang to the Board of Directors Jan 28
New 90-day high: US$1.55 Jan 27
New 90-day high: US$1.21 Dec 11
Regulus Therapeutics announces closing of $19.4M private placement Dec 08
Regulus Therapeutics Collaborates with Bio-Techne Corporation for Biomarker Development Dec 03
Regulus Therapeutics Inc. announced that it expects to receive $19.091813 million in funding Dec 02
New 90-day high: US$0.66 Nov 20
Revenue beats expectations, earnings disappoint Nov 08
Regulus Therapeutics EPS beats by $0.17, beats on revenue Nov 05
Regulus Therapeutics Announces First Patient Dosed in Phase 1b Clinical Trial of RGLS4326 for the Treatment of Patients with Autosomal Dominant Polycystic Kidney Disease (ADPKD) Oct 16
Analysts lower revenue estimates to US$3.77m Sep 03
New 90-day low - US$0.53 Sep 01
New 90-day low - US$0.61 Aug 16
First half earnings released Aug 14
New 90-day high - US$0.96 Jul 21 Rendimenti per gli azionisti RGLS US Biotechs US Mercato 7D -15.7% -4.2% 0.2% 1Y -27.6% -3.0% 23.1%
Vedi i rendimenti completi degli azionisti
Ritorno vs Industria: RGLS ha avuto una performance inferiore rispetto al US Biotechs che ha registrato un rendimento -3 % nell'ultimo anno.
Rendimento vs Mercato: RGLS ha avuto una performance inferiore al mercato US che ha registrato un rendimento 23.1 % nell'ultimo anno.
Volatilità dei prezzi Is RGLS's price volatile compared to industry and market? RGLS volatility RGLS Average Weekly Movement 12.1% Biotechs Industry Average Movement 11.4% Market Average Movement 5.9% 10% most volatile stocks in US Market 18.3% 10% least volatile stocks in US Market 3.0%
Prezzo delle azioni stabile: Negli ultimi 3 mesi il prezzo delle azioni di RGLS è stato volatile rispetto al mercato US.
Volatilità nel tempo: La volatilità settimanale ( 12% ) di RGLS è rimasta stabile nell'ultimo anno, ma è comunque superiore al 75% delle azioni US.
Informazioni sull'azienda Regulus Therapeutics Inc. è una società biofarmaceutica in fase clinica che si occupa della scoperta e dello sviluppo di farmaci che hanno come bersaglio i microRNA per il trattamento di una serie di malattie negli Stati Uniti. I suoi prodotti candidati includono RGLS8429, un oligonucleotide anti-miR di nuova generazione che ha come bersaglio il miR-17, in fase di sperimentazione clinica di Fase 1b per il trattamento della malattia policistica renale autosomica dominante. L'azienda sta inoltre sviluppando una pipeline di prodotti farmaceutici preclinici per strategie di rilascio selettivo dell'organo bersaglio.
Mostra di più Regulus Therapeutics Inc. Riepilogo dei fondamenti Come si confrontano gli utili e i ricavi di Regulus Therapeutics con la sua capitalizzazione di mercato? RGLS statistiche fondamentali Capitalizzazione di mercato US$78.60m Guadagni(TTM ) -US$41.63m Ricavi(TTM ) n/a
Guadagni e ricavi Statistiche chiave sulla redditività dall'ultima relazione sugli utili (TTM) RGLS Conto economico (TTM ) Ricavi US$0 Costo del fatturato US$22.62m Profitto lordo -US$22.62m Altre spese US$19.01m Guadagni -US$41.63m
Ultimi guadagni dichiarati
Sep 30, 2024
Prossima data di guadagno
n/a
Utile per azione (EPS) -0.64 Margine lordo 0.00% Margine di profitto netto 0.00% Rapporto debito/patrimonio netto 0%
Come si è comportato RGLS nel lungo periodo?
Vedi performance storica e confronto
Analisi aziendale e situazione dei dati finanziari Dati Ultimo aggiornamento (ora UTC) Analisi dell'azienda 2025/02/11 09:41 Prezzo dell'azione a fine giornata 2025/02/11 00:00 Guadagni 2024/09/30 Guadagni annuali 2023/12/31
Fonti dei dati I dati utilizzati nella nostra analisi aziendale provengono da S&P Global Market Intelligence LLC . I seguenti dati sono utilizzati nel nostro modello di analisi per generare questo report. I dati sono normalizzati, il che può comportare un ritardo nella disponibilità della fonte.
Pacchetto Dati Tempistica Esempio Fonte USA * Dati finanziari della società 10 anni Conto economico Rendiconto finanziario Bilancio Stime di consenso degli analisti +3 anni Previsioni finanziarie Obiettivi di prezzo degli analisti Prezzi di mercato 30 anni Prezzi delle azioni Dividendi, scissioni e azioni Proprietà 10 anni Top azionisti Insider trading Gestione 10 anni Team di leadership Consiglio di amministrazione Sviluppi principali 10 anni
* Esempio per i titoli statunitensi, per i titoli non statunitensi si utilizzano forme e fonti normative equivalenti.
Se non specificato, tutti i dati finanziari si basano su un periodo annuale ma vengono aggiornati trimestralmente. Si tratta dei cosiddetti dati TTM (Trailing Twelve Month) o LTM (Last Twelve Month). Per saperne di più .
Modello di analisi e Snowflake I dettagli del modello di analisi utilizzato per generare questo report sono disponibili sulla nostra pagina Github ; abbiamo anche guide su come utilizzare i nostri report e tutorial su Youtube .
Scoprite il team di livello mondiale che ha progettato e realizzato il modello di analisi Simply Wall St.
Metriche di settore e industriali Le nostre metriche di settore e di sezione sono calcolate ogni 6 ore da Simply Wall St; i dettagli del nostro processo sono disponibili su Github .
Fonti analitiche Regulus Therapeutics Inc. è coperta da 17 analisti. 6 di questi analisti ha fornito le stime di fatturato o di utile utilizzate come input per il nostro report. Le stime degli analisti vengono aggiornate nel corso della giornata.
Analista Istituzione James Birchenough BMO Capital Markets Equity Research James Birchenough BMO Capital Markets U.S. (Historical) Madhu Kumar B. Riley Securities, Inc.
Mostra 14 altri analisti 
